Literature DB >> 15530558

p38 MAP kinase's emerging role as a tumor suppressor.

Dmitry V Bulavin1, Albert J Fornace.   

Abstract

The p38 proteins are an evolutionally conserved family of mitogen-activated protein kinases (MAPK). Recent studies have led to progress in our understanding the roles of p38 MAPK in regulation of tumorigenesis through key cellular growth-control mechanisms. Along with the previously well-characterized proapoptotic functions, new data highlight the critical contributions of p38 MAPK in the negative regulation of cell cycle progression. This review will focus on the ability of p38 MAPK to positively regulate several tumor suppressor (p53- and Rb-dependent) pathways and to attenuate oncogenic (Cdc25A and Cdc25B phosphatases) signals. The concept of p38 MAPK as a potential tumor suppressor will be developed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530558     DOI: 10.1016/S0065-230X(04)92005-2

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  99 in total

1.  Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.

Authors:  Bei Zhang; Xueya Wang; Fengfeng Cai; Weijie Chen; Uli Loesch; Johannes Bitzer; Xiao Yan Zhong
Journal:  Tumour Biol       Date:  2012-07-07

2.  GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells.

Authors:  Sofia Cárdenas; Cecilia Colombero; Laura Panelo; Rambabu Dakarapu; John R Falck; Monica A Costas; Susana Nowicki
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-11-21       Impact factor: 4.698

3.  CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins.

Authors:  Tobias Engl; Borna Relja; Dana Marian; Christa Blumenberg; Iris Müller; Wolf-Dietrich Beecken; Jon Jones; Eva M Ringel; Jürgen Bereiter-Hahn; Dietger Jonas; Roman A Blaheta
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 4.  Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?

Authors:  Aparna C Ranganathan; Alejandro P Adam; Lin Zhang; Julio A Aguirre-Ghiso
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

Review 5.  Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.

Authors:  Yingxi Xu; Na Li; Rong Xiang; Peiqing Sun
Journal:  Trends Biochem Sci       Date:  2014-05-09       Impact factor: 13.807

6.  Maintaining a regular physical activity aggravates intramuscular tumor growth in an orthotopic liposarcoma model.

Authors:  Mohamad Assi; Frédéric Derbré; Luz Lefeuvre-Orfila; Dany Saligaut; Nathalie Stock; Mickael Ropars; Amélie Rébillard
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

Authors:  Lan Xiao; Yue-bo Yang; Xiao-mao Li; Cheng-fang Xu; Tian Li; Xiao-yun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-20       Impact factor: 4.553

8.  p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.

Authors:  Bangxing Hong; Haiyan Li; Mingjun Zhang; Jingda Xu; Yong Lu; Yuhuan Zheng; Jianfei Qian; Jeffrey T Chang; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-05-16       Impact factor: 7.396

Review 9.  Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.

Authors:  J Kay Noel; Sheila Crean; Janet E Claflin; Gayatri Ranganathan; Heather Linz; Michael Lahn
Journal:  Med Oncol       Date:  2008-01-19       Impact factor: 3.064

10.  HBP1-mediated transcriptional regulation of DNA methyltransferase 1 and its impact on cell senescence.

Authors:  Kewu Pan; Yifan Chen; Mendel Roth; Weibin Wang; Shuya Wang; Amy S Yee; Xiaowei Zhang
Journal:  Mol Cell Biol       Date:  2012-12-17       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.